{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T21:10:11Z","timestamp":1793394611261,"version":"4.5.0"},"reference-count":42,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100006545","name":"National Institute on Minority Health and Health Disparities","doi-asserted-by":"crossref","award":["R01MD009223"],"award-info":[{"award-number":["R01MD009223"]}],"id":[{"id":"10.13039\/100006545","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Rheumatic Disease Clinics of North America"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1016\/j.rdc.2018.06.003","type":"journal-article","created":{"date-parts":[[2018,9,7]],"date-time":"2018-09-07T04:56:04Z","timestamp":1536296164000},"page":"561-569","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Nonproliferative Forms of Lupus Nephritis"],"prefix":"10.1016","volume":"44","author":[{"given":"Andrew S.","family":"Bomback","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.rdc.2018.06.003_bib1","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1681\/ASN.2010050472","article-title":"Updates on the treatment of lupus nephritis","volume":"21","author":"Bomback","year":"2010","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"4","key":"10.1016\/j.rdc.2018.06.003_bib2","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/ki.2011.354","article-title":"A\u00a0composite urine biomarker reflects interstitial inflammation in lupus nephritis kidney biopsies","volume":"81","author":"Zhang","year":"2012","journal-title":"Kidney Int"},{"issue":"5","key":"10.1016\/j.rdc.2018.06.003_bib3","doi-asserted-by":"crossref","first-page":"R143","DOI":"10.1186\/ar2816","article-title":"Urinary TWEAK as a biomarker of lupus nephritis: a multicenter cohort study","volume":"11","author":"Schwartz","year":"2009","journal-title":"Arthritis Res Ther"},{"issue":"6","key":"10.1016\/j.rdc.2018.06.003_bib4","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1002\/acr.21664","article-title":"American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis","volume":"64","author":"Hahn","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"3","key":"10.1016\/j.rdc.2018.06.003_bib5","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1053\/j.ajkd.2013.06.002","article-title":"KDOQI US commentary on the 2012 KDIGO clinical practice guideline for glomerulonephritis","volume":"62","author":"Beck","year":"2013","journal-title":"Am J Kidney Dis"},{"issue":"6","key":"10.1016\/j.rdc.2018.06.003_bib6","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1038\/sj.ki.5002118","article-title":"The ISN\/RPS 2003 classification of lupus nephritis: an assessment at 3 years","volume":"71","author":"Markowitz","year":"2007","journal-title":"Kidney Int"},{"issue":"5 Suppl 1","key":"10.1016\/j.rdc.2018.06.003_bib7","first-page":"S1","article-title":"K\/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease","volume":"43","year":"2004","journal-title":"Am J Kidney Dis"},{"issue":"20","key":"10.1016\/j.rdc.2018.06.003_bib8","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1056\/NEJM199311113292004","article-title":"The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group","volume":"329","author":"Lewis","year":"1993","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1016\/j.rdc.2018.06.003_bib9","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes","volume":"345","author":"Lewis","year":"2001","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.rdc.2018.06.003_bib10","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1053\/j.ajkd.2006.04.077","article-title":"Combination therapy with an angiotensin receptor blocker and an ACE inhibitor in proteinuric renal disease: a systematic review of the efficacy and safety data","volume":"48","author":"MacKinnon","year":"2006","journal-title":"Am J Kidney Dis"},{"issue":"7","key":"10.1016\/j.rdc.2018.06.003_bib11","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1093\/rheumatology\/ken208","article-title":"Angiotensin-converting enzyme\u00a0inhibitors delay the occurrence of renal involvement and are associated with a decreased risk of disease activity in patients with systemic lupus erythematosus\u2013results from LUMINA (LIX): a multiethnic US cohort","volume":"47","author":"Duran-Barragan","year":"2008","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"10.1016\/j.rdc.2018.06.003_bib12","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1191\/0961203306lu2306rr","article-title":"The renin-angiotensin system in lupus: physiology, genes and practice, in animals and humans","volume":"15","author":"Teplitsky","year":"2006","journal-title":"Lupus"},{"issue":"3","key":"10.1016\/j.rdc.2018.06.003_bib13","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1111\/j.1523-1755.2004.00462.x","article-title":"An ACE inhibitor reduces Th2 cytokines and TGF-beta1 and TGF-beta2 isoforms in murine lupus nephritis","volume":"65","author":"De Albuquerque","year":"2004","journal-title":"Kidney Int"},{"issue":"1","key":"10.1016\/j.rdc.2018.06.003_bib14","doi-asserted-by":"crossref","first-page":"R5","DOI":"10.1186\/ar2353","article-title":"The role of aldosterone blockade in murine lupus nephritis","volume":"10","author":"Monrad","year":"2008","journal-title":"Arthritis Res Ther"},{"issue":"24","key":"10.1016\/j.rdc.2018.06.003_bib15","doi-asserted-by":"crossref","first-page":"e7099","DOI":"10.1097\/MD.0000000000007099","article-title":"The value of repeat biopsy in lupus nephritis flares","volume":"96","author":"Narvaez","year":"2017","journal-title":"Medicine (Baltimore)"},{"issue":"12","key":"10.1016\/j.rdc.2018.06.003_bib16","doi-asserted-by":"crossref","first-page":"3712","DOI":"10.1093\/ndt\/gfp359","article-title":"The clinical relevance of a repeat biopsy in lupus nephritis flares","volume":"24","author":"Daleboudt","year":"2009","journal-title":"Nephrol Dial Transplant"},{"issue":"3","key":"10.1016\/j.rdc.2018.06.003_bib17","doi-asserted-by":"crossref","first-page":"453","DOI":"10.3109\/14397595.2013.844293","article-title":"The clinical significance of serial kidney biopsies in lupus nephritis","volume":"24","author":"Alsuwaida","year":"2014","journal-title":"Mod Rheumatol"},{"issue":"12","key":"10.1016\/j.rdc.2018.06.003_bib18","first-page":"2822","article-title":"Serial renal biopsy in systemic lupus erythematosus","volume":"27","author":"Bajaj","year":"2000","journal-title":"J\u00a0Rheumatol"},{"issue":"12","key":"10.1016\/j.rdc.2018.06.003_bib19","doi-asserted-by":"crossref","first-page":"3014","DOI":"10.1093\/ndt\/gft272","article-title":"The value of repeat biopsy in the management of lupus nephritis: an international multicentre study in a large cohort of patients","volume":"28","author":"Pagni","year":"2013","journal-title":"Nephrol Dial Transpl"},{"issue":"3","key":"10.1016\/j.rdc.2018.06.003_bib20","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/S0272-6386(99)70082-X","article-title":"Clinical and prognostic value of serial renal biopsies in lupus nephritis","volume":"34","author":"Moroni","year":"1999","journal-title":"Am J Kidney Dis"},{"issue":"16","key":"10.1016\/j.rdc.2018.06.003_bib21","first-page":"2890","article-title":"Changes in pathological pattern and treatment regimens based on repeat renal biopsy in lupus nephritis","volume":"125","author":"Wang","year":"2012","journal-title":"Chin Med J (Engl)"},{"issue":"1","key":"10.1016\/j.rdc.2018.06.003_bib22","doi-asserted-by":"crossref","first-page":"e000004","DOI":"10.1136\/lupus-2013-000004","article-title":"Value of repeat biopsy in lupus nephritis flares","volume":"1","author":"Greloni","year":"2014","journal-title":"Lupus Sci Med"},{"issue":"4","key":"10.1016\/j.rdc.2018.06.003_bib23","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1177\/0961203317726864","article-title":"The clinical relevance of repeat renal biopsies in the management of lupus nephritis: a South African experience","volume":"27","author":"Tannor","year":"2018","journal-title":"Lupus"},{"issue":"2","key":"10.1016\/j.rdc.2018.06.003_bib24","doi-asserted-by":"crossref","first-page":"120","DOI":"10.5414\/CNP57120","article-title":"Minimal change disease in systemic lupus erythematosus","volume":"57","author":"Dube","year":"2002","journal-title":"Clin Nephrol"},{"issue":"6","key":"10.1016\/j.rdc.2018.06.003_bib25","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1053\/ajkd.2002.36875","article-title":"SLE and idiopathic nephrotic syndrome: coincidence or not?","volume":"40","author":"Hertig","year":"2002","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"10.1016\/j.rdc.2018.06.003_bib26","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1681\/ASN.2004050350","article-title":"Glomerular podocytopathy in patients with systemic lupus erythematosus","volume":"16","author":"Kraft","year":"2005","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"4","key":"10.1016\/j.rdc.2018.06.003_bib27","doi-asserted-by":"crossref","first-page":"585","DOI":"10.2215\/CJN.06720615","article-title":"Clinical-morphological features and outcomes of lupus podocytopathy","volume":"11","author":"Hu","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"issue":"4","key":"10.1016\/j.rdc.2018.06.003_bib28","doi-asserted-by":"crossref","first-page":"547","DOI":"10.2215\/CJN.01880216","article-title":"Lupus podocytopathy: a distinct entity","volume":"11","author":"Bomback","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"issue":"4","key":"10.1016\/j.rdc.2018.06.003_bib29","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1681\/ASN.2008060665","article-title":"Randomized, controlled trial of prednisone, cyclophosphamide, and cyclosporine in lupus membranous nephropathy","volume":"20","author":"Austin","year":"2009","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"12","key":"10.1016\/j.rdc.2018.06.003_bib30","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1038\/sj.ki.5002553","article-title":"Cyclosporin in idiopathic glomerular disease associated with the nephrotic syndrome : workshop recommendations","volume":"72","author":"Cattran","year":"2007","journal-title":"Kidney Int"},{"issue":"1","key":"10.1016\/j.rdc.2018.06.003_bib31","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1177\/0961203306073167","article-title":"A\u00a0pilot study on tacrolimus treatment in membranous or quiescent lupus nephritis with proteinuria resistant to angiotensin inhibition or blockade","volume":"16","author":"Tse","year":"2007","journal-title":"Lupus"},{"issue":"4","key":"10.1016\/j.rdc.2018.06.003_bib32","doi-asserted-by":"crossref","first-page":"c330","DOI":"10.1159\/000235952","article-title":"Clinical assessment of tacrolimus therapy in lupus nephritis: one-year follow-up study in a single center","volume":"113","author":"Asamiya","year":"2009","journal-title":"Nephron Clin Pract"},{"issue":"6","key":"10.1016\/j.rdc.2018.06.003_bib33","doi-asserted-by":"crossref","first-page":"606","DOI":"10.3109\/s10165-009-0218-5","article-title":"Efficacy and safety of tacrolimus for lupus nephritis: a placebo-controlled double-blind multicenter study","volume":"19","author":"Miyasaka","year":"2009","journal-title":"Mod Rheumatol"},{"issue":"1","key":"10.1016\/j.rdc.2018.06.003_bib34","first-page":"6","article-title":"Tacrolimus is effective for lupus nephritis patients with persistent proteinuria","volume":"28","author":"Uchino","year":"2010","journal-title":"Clin Exp Rheumatol"},{"issue":"21","key":"10.1016\/j.rdc.2018.06.003_bib35","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa043731","article-title":"Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis","volume":"353","author":"Ginzler","year":"2005","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.rdc.2018.06.003_bib36","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1681\/ASN.2008101028","article-title":"Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis","volume":"20","author":"Appel","year":"2009","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"2","key":"10.1016\/j.rdc.2018.06.003_bib37","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1038\/ki.2009.412","article-title":"Mycophenolate mofetil and intravenous cyclophosphamide are similar as induction therapy for class V lupus nephritis","volume":"77","author":"Radhakrishnan","year":"2010","journal-title":"Kidney Int"},{"issue":"4","key":"10.1016\/j.rdc.2018.06.003_bib38","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1002\/art.34359","article-title":"Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study","volume":"64","author":"Rovin","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.rdc.2018.06.003_bib39","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1002\/art.38260","article-title":"Efficacy and safety of abatacept in lupus nephritis: a twelve-month, randomized, double-blind study","volume":"66","author":"Furie","year":"2014","journal-title":"Arthritis Rheumatol"},{"issue":"10","key":"10.1016\/j.rdc.2018.06.003_bib40","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1681\/ASN.2007121272","article-title":"Successful treatment of class V+IV lupus nephritis with multitarget therapy","volume":"19","author":"Bao","year":"2008","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"1","key":"10.1016\/j.rdc.2018.06.003_bib41","doi-asserted-by":"crossref","first-page":"18","DOI":"10.7326\/M14-1030","article-title":"Multitarget therapy for induction treatment of lupus nephritis: a randomized trial","volume":"162","author":"Liu","year":"2015","journal-title":"Ann Intern Med"},{"issue":"12","key":"10.1016\/j.rdc.2018.06.003_bib42","doi-asserted-by":"crossref","first-page":"3671","DOI":"10.1681\/ASN.2017030263","article-title":"Multitarget therapy for maintenance treatment of lupus nephritis","volume":"28","author":"Zhang","year":"2017","journal-title":"J\u00a0Am Soc Nephrol"}],"container-title":["Rheumatic Disease Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889857X18300565?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889857X18300565?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T11:16:04Z","timestamp":1760181364000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889857X18300565"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":42,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["S0889857X18300565"],"URL":"https:\/\/doi.org\/10.1016\/j.rdc.2018.06.003","relation":{},"ISSN":["0889-857X"],"issn-type":[{"value":"0889-857X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nonproliferative Forms of Lupus Nephritis","name":"articletitle","label":"Article Title"},{"value":"Rheumatic Disease Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rdc.2018.06.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}